Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Retatrutide vs Semaglutide
An educational, source-based comparison of Retatrutide and Semaglutide — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic peptide that simultaneously agonizes GLP-1, GIP, and glucagon receptors. The glucagon component is hypothesized to add energy expenditure on top of the appetite suppression and insulinotropic effects of GLP-1/GIP.
- Obesity and weight loss (Phase 3)
- Type 2 diabetes
- NAFLD/MASH
- • Investigational; not FDA-approved (Phase 3 ongoing).
- • GI side effects common, similar to other incretin therapies.
- • Requires physician oversight.
A long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central GLP-1 receptors.
- Type 2 diabetes (Ozempic, Rybelsus)
- Obesity / chronic weight management (Wegovy)
- Cardiovascular risk reduction (SELECT trial)
- • FDA-approved with established safety profile but real side effects (GI, pancreatitis risk, gallbladder events).
- • Requires physician oversight and prescription.
- • Compounded versions vary in quality.
Retatrutide vs Semaglutide — Key differences
- Class: Retatrutide is classified as Metabolic · Incretin, while Semaglutide is Metabolic · Incretin.
- Primary research focus: Retatrutide — obesity and weight loss (phase 3); Semaglutide — type 2 diabetes (ozempic, rybelsus).
- Tag: Weight loss vs Weight loss.